Myomo (MYO) Long-Term Investments (2022 - 2023)
Myomo (MYO) posted Long-Term Investments of $32648.0 for Q3 2023, down 68.23% on a QoQ basis from $102773.0 in Q2 2023, and down 78.11% year-over-year from $149140.0 in Q3 2022.
Myomo (MYO) Long-Term Investments (2022 - 2023) Analysis & Trends
Myomo's Long-Term Investments history runs 2 years deep, the most recent figure standing at $32648.0 for Q3 2023.
- Quarterly Long-Term Investments fell 78.11% year-over-year to $32648.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $32648.0 (down 78.11% YoY) and the FY2022 annual result came in at $132489.0, changed N/A from the prior year.
- Long-Term Investments was $32648.0 for Q3 2023 at Myomo, down from $102773.0 in the prior quarter.
- Across five years, Long-Term Investments topped out at $199000.0 in Q1 2022 and bottomed at $32648.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.26 Bn | 175.96 Bn | 6.27 Bn | 1.09 Bn |
| 2 | Stryker | 128.79 Bn | 125.92 Bn | 3.81 Bn | - |
| 3 | Medtronic | 108.56 Bn | 99.34 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 68.31 Bn | 66.86 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 47.27 Bn | 43.60 Bn | 1.29 Bn | 285.60 Mn |
| 6 | Dexcom | 28.42 Bn | 27.31 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 28.40 Bn | 26.12 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | 121.00 Mn |
| 9 | Koninklijke Philips | 25.52 Bn | 22.40 Bn | 2.07 Bn | 166.25 Mn |
| 10 | Myomo | 42.80 Mn | 23.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 32,648.00 |
| Jun 30, 2023 | 102,773.00 |
| Mar 31, 2023 | 115,287.00 |
| Dec 31, 2022 | 132,489.00 |
| Sep 30, 2022 | 149,140.00 |
| Jun 30, 2022 | 165,792.00 |
| Mar 31, 2022 | 199,000.00 |